Dupixent® (dupilumab) approved by european commission for children aged 6 to 11 years with severe asthma with type 2 inflammation

Approval based on phase 3 data showing dupixent significantly reduced severe asthma attacks and also improved lung function and health-related quality of life for children data reinforce well-established safety profile of dupixent tarrytown, n.y. and paris , april 7, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced that the european commission (ec) has expanded the marketing authorization for dupixent® (dupilumab) in the european union.
REGN Ratings Summary
REGN Quant Ranking